Dr. Courtney is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Blvd
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-645-2610
Summary
- Dr. Kevin Courtney is a medical oncologist in Dallas, TX with University of Texas Southwestern Medical Center and the UT Southwestern Harold C. Simmons Comprehensive Cancer Center. He received his MD and his PhD in Molecular Cancer Biology from Duke University School of Medicine. He specializes in genitourinary oncology.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008
- University of California (San Francisco)Residency, Internal Medicine, 2002 - 2005
- Duke University School of MedicineClass of 2002
Certifications & Licensure
- TX State Medical License 2012 - 2025
- MA State Medical License 2005 - 2012
- CA State Medical License 2004 - 2005
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Publications & Presentations
PubMed
- 43 citationsAnalysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.Robert C. Quackenbush, Gary W. Reuther, Juli P. Miller, Kevin D. Courtney, Warren S. Pear
Blood. 2000-05-01 - 23 citationsEmergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.Andrea Loehr, Arif Hussain, Akash Patnaik, Alan H Bryce, Daniel Castellano
European Urology. 2023-03-01 - 951 citationsThe PI3K Pathway As Drug Target in Human CancerKevin D. Courtney, Ryan B. Corcoran, Jeffrey A. Engelman
Journal of Clinical Oncology. 2010-02-20
Journal Articles
- Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the in Vitro Integrity of T-cells from Cancer PatientsKevin Courtney, Yull Arriaga, Barbara Haley, John C Mansour, Ponciano D Cruz, David Harker, Farshid Araghizadeh, Clinical Cancer Research
Press Mentions
- UTSW’s Simmons Cancer Center Awarded More Than $11.5 Million in CPRIT FundingSeptember 6th, 2024
- Children’s Research Institute at UT Southwestern Scientists Discover Kidney Cancers Rely on Mitochondrial Metabolism to MetastasizeAugust 14th, 2024
- Findings Establish PT2385 as a Highly Specific HIF-2 Inhibitor for Patients with Clear Cell RCCFebruary 27th, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: